Skip to content
DataLookout
Menu

K-BOOSTNCT07622017

KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 46 words
    • Start date changed from estimate of Jul 2026 to Oct 5, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Clinical Complete Response (cCR) Rate at Week 24
Timeframe: Week 24

Secondary (4)

Pathological Complete Response (pCR) Rate
Progression-Free Survival (PFS)
Overall Survival (OS)
Incidence of Adverse Events

Arms and interventions

Intratumoral KRC-01 injections combined with standard chemoradiotherapyExperimental

Participants receive intratumoral KRC-01 injections (8 injections) combined with standard long-course chemoradiotherapy (radiotherapy: 50 Gy in 25 fractions plus capecitabine 825 mg/m² orally twice daily for 5 weeks) and consolidation chemotherapy with CAPOX or FOLFOX according to investigator decision and institutional practice. Surgery with total mesorectal excision (TME) may be performed depending on tumor response and multidisciplinary team assessment.

Drugs: KRC-01 (KORTUC), Capecitabine, CAPOX, FOLFOX

Radiation: Radiotherapy

Procedures: Optionnal TME

Sites

2 sites in 1 country